EHA 2024: Updates in the Treatment of CLL - Episode 14
Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.
Dr Coombs to Group:What implications may these findings have on treatment sequencing? Is there a potential role of testing for acquired mutations upon disease progression?